https://www.selleckchem.com/products/ABT-888.html
INTRODUCTION In this article we advance a potential explanation for the incidence of cardiovascular (CV) and cardiometabolic risk in patients undergoing androgen deprivation therapy (ADT) for prostate cancer. Our conceptual model involves the differential impact of gonadotropin-releasing hormone (GnRH) agonists and antagonists on the follicle-stimulating hormone (FSH) system. MATERIALS AND METHODS Authors searched online repositories and meeting abstract databases for relevant materials. RESULTS Mounting evidence links FSH with developm
Curtir
Comentario
Compartilhar
